Coriolus versicolor polysaccharide peptide slows progression
of advanced non-small cell lung cancer.
Tsang KW, Lam CL, Yan C, Mak JC, Ooi GC, Ho JC, Lam B, Man
R, Sham JS, Lam WK.
Department of Medicine, The University of Hong Kong,
Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
kwttsang@hku.hk
BACKGROUND:
Non-small cell lung cancer (NSCLC) is a leading cause of cancer
deaths, and over 60% of patients present with advanced stages.
Although polysaccharide peptides (PSP), isolated from the
fungus Coriolus versicolor, have been reported to have anti-tumor
effects, its clinical efficacy has not been properly evaluated.
METHODS:
Double-blind placebo-controlled randomized study to evaluate
the effects of 28-day administration of PSP (Windsor Pharmaceutical,
Hong Kong) on patients, who had completed conventional treatment
for advanced NSCLC.
RESULTS: Thirty-four
patients, with no significant difference in their baseline
demographic, clinical or tumor characteristics, or previous
treatment regimes (P>0.05) were recruited into each of
the PSP and control arms. After 28-day treatment, there was
a significant improvement in blood leukocyte and neutrophil
counts, serum IgG and IgM, and percent of body fat among the
PSP, but not the control, patients (P<0.05). Although the
evaluable PSP patients did not improve in NSCLC-related symptoms,
there were significantly less PSP patients withdrawn due to
disease progression, than their control counterparts (5.9
and 23.5%, respectively; P=0.04; OR 4.00). There was no reported
adverse reaction attributable to the trial medications.
CONCLUSION:
PSP treatment appears to be associated with slower deterioration
in patients with advanced NSCLC.
Publication Types:
· Clinical Trial
· Clinical Trial, Phase II
· Randomized Controlled Trial
Diane Bilodeau, PhD
Chargée de projets/ Project Manager
Affaires scientifiques/ Scientific Affairs
Atrium Biotechnologies PSP Now available
in the Pharmcacy
PSP
Classic PSP-II
|
